Clinical Trials Search at Vanderbilt-Ingram Cancer Center
(VELA) Study of BLU-222 in Advanced Solid Tumors
Miscellaneous
Miscellaneous
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of
BLU-222, a selective inhibitor of CDK2.
tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of
BLU-222, a selective inhibitor of CDK2.
Miscellaneous
I/II
Kennedy, Laura
NCT05252416
VICCBREP2275
